Abstract: A personal care composition comprising N-aralkylcarbonyldiamines. When such compounds are used in personal care compositions, they have been unexpectedly shown to enhance cell proliferation and epidermal thickness, traits associated with younger, healthy looking skin.

Abstract: A method, usage and kit-of-parts for decolorizing human keratin fibers, which were colored with oxidation dyes and/or partially-oxidizing dyes, comprising the application of an agent to the dyed keratin fibers, which contains in a cosmetic carrier at least one compound of the Formula (I) wherein X denotes a bivalent organic radical of the Formula (II) or a direct bond,

Abstract: The present invention relates to a cosmetic method comprising applying a migration imparting agent for adipose-derived stem cells to the skin, thereby allowing adipose-derived stem cells to migrate to the dermal layer and improving a skin condition. The present invention also relates to an external skin preparation for use in the cosmetic method, the external skin preparation comprising a migration imparting agent allowing adipose-derived stem cells to migrate to the dermal layer by application to the skin. The present invention further relates to a migration imparting agent for adipose-derived stem cells, comprising at least one of a polyol compound and a hydrophilic biomaterial. The present invention further relates to a method of screening for a component for use in a cosmetic method for improving a skin condition, comprising evaluating migratory activity of adipose-derived stem cells by using a prepared medium containing a sample.

Abstract: Topical compositions with improved sun protection factor and UVA protection factor are described. The compositions have sunscreen and polymer of D-glucose and/or nonionic, branched heteroglycan and specific diol compounds to enhance skin protection benefits.

Abstract: The invention relates to a nail polish composition containing at least one film-forming agent, a plasticizer, and a solvent. Said composition is characterized in that it also includes one or more oligomer(s) having a molar mass of 1500 g/mol and/or a glass transition temperature Tg greater than 25° C. Said oligomer has dual acrylic or methacrylic bonds available for reacting with groups without containing any agent for cross-linking the oligomer, such as a photoinitiator. The method for applying the nail polish includes consecutively applying such a photoinitiator-free composition and a similar photoinitiator-containing composition followed by visible-light cross-linking. The nail polish has longer-lasting sheen and better hardness than solvent-based nail polishes and also comes on and off much more quickly than a gel-based nail polish.

Abstract: Disclosed are compositions and methods for their use that can be used individually or in combination. The compositions have the ability to treat a wide range of skin and skin conditions, and particularly men's skin.

Abstract: Disclosed are compositions and methods for protecting hair against heat comprising applying to hair compositions containing silicone and silicone polyether copolymers with groups having amino, hydroxyl and/or alkoxy functionalities.

Abstract: The present invention provides a topical composition comprising (a) 0.5 to 25 weight percent of glycerin; (b) 0.1 to 5 weight percent of cetearyl olivate; (c) 0.1 to 5 weight percent of sorbitan olivate; and (d) 0.01.to 1 weight percent of extract of Pichia anomala; wherein the composition is substantially free of fatty alcohols and is in the form of a gel cream.

Abstract: The present invention provides stable antioxidant cosmetic formulations for topical use comprising green tea extract in combination with additional active compounds having the surprising ability to exert antioxidant effect on the skin, the use said formulations, as well as a method for reducing and/or preventing oxidative stress in keratinous tissues.

Abstract: Disclosed are dosage forms comprising a capsule and a fill material, comprising (a) a fill material comprising a dispersion of an active agent and a polymer, the dispersion being granulated, (b) an osmogen, and (c) a glidant. In one embodiment, the dispersion comprises 10 wt % to 90 wt % of the fill material, the osmogen comprises from 5 wt % to 40 wt % of the fill material, and the glidant comprises at least 0.1 wt % of the fill material.

Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: Provided herein is a liposome comprising: a) a conjugate comprising a lysophospholipid and a photosensitizer; b) a first derivatized phospholipid comprising a first phospholipid and a strained cyclooctyne moiety; c) a second derivatized phospholipid comprising a second phospholipid and a polyethylene glycol polymer; and d) a cationic or anionic lipid. Also provided herein is a liposome comprising: a) a conjugate comprising a lysophospholipid and a photosensitizer; b) a first derivatized phospholipid comprising a first phospholipid and a targeting moiety; c) a second derivatized phospholipid comprising a second phospholipid and a polyethylene glycol polymer; and d) a cationic or anionic lipid. The liposomes provided herein can be used, for example, in the treatment of cancer or in the imaging of cancer tumors.

Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Abstract: The invention provides liposome compositions comprising liposomes encapsulating cyclodextrins that both bear ionizable functional groups, such as on their solvent-exposed surfaces, and encompass therapeutic agents, as well as uses thereof.

Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.

Abstract: The present disclosure provides a temperature-responsive composition including a nitric oxide donor and a carrier. The nitric oxide donor is a pH-dependent material, and the carrier is provided for carrying the nitric oxide donor with an effective amount. The carrier includes a protective agent and an organic protic acid. A transition temperature of the temperature-responsive composition is larger than or equal to 28° C. and less than or equal to 37° C.

Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

Abstract: A nozzle, an apparatus, and a method are provided for mass production of dual-layer microparticles used as microcarriers. The nozzle includes a nozzle body having a first fluid passageway and a cover mounted to the nozzle body and having a second fluid passageway. A plurality of extension tubes is communicated with an end of the first fluid passageway and is spaced from each other. Each extension tube includes an outlet port distant to the first fluid passageway. A plurality of sleeves is communicated with the second fluid passageway. Each sleeve includes an opening distant to the second fluid passageway. Each extension tube extends into one of the sleeves. An outer wall of each extension tube is spaced from an inner wall of one of the sleeves. The outlet port of each extension tube is located between the second fluid passageway and the opening of one of the sleeves.

Abstract: This disclosure features gastro-retentive (GR) modified release pharmaceutical dosage forms (e.g., solid dosage forms, e.g., tablets, e.g., bilayer tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the dosage form.

Abstract: The invention relates to a pharmaceutical formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a high drug load part and an immediate release part. In addition, the invention relates to a formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a first layer and a surfactant in a layer beneath the first layer. The pharmaceutical composition is particularly suitable for use as a medicament.

Abstract: A long-acting pharmaceutical composition comprising at least one amphetamine salt is provided. The composition comprises an immediate release component, a delayed release component, and a sustained release component comprising one or more amphetamine salts. The sustained release component comprises a sustained release layer and a delayed release layer, such that the delayed release layer is coated onto the sustained release layer. The time (Tmax) to achieve Cmax after administration of said composition is between 7-10 hours.

Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Abstract: Methods for treating and/or delaying onset of dysplastic lesions in the bronchial airway of an individual comprise delivering to the respiratory track of the individual an inhalable dry powder composition including an effective amount of myo-inositol.

Abstract: The subject invention pertains to methods and compositions for the treatment of erectile dysfunction (ED) (e.g., impotence) in a subject in need thereof utilizing one or more cannabinoid and one or more anti-ED drug.

Abstract: The invention provides compositions and methods for treating seizure disorders such as epilepsy in humans and animals using, in a first embodiment, the combination of (i) an effective amount of a barbiturate drug, such as phenobarbital or primidone, which solely enhances GABAergic inhibition in a patient suffering a seizure disorder; and (ii) phytocannabinoid cannabidiol (CBD) in a dosage amount sufficient to overcome the hepatic metabolic effect stimulated by the barbiturate drug and provide bioavailable CBD to the patient in clinically efficacious amounts.

Abstract: A method for treating alcohol dependence or alcohol abuse in a subject comprising administering to the subject a composition comprising an effective amount of memantine, wherein the effective amount of memantine is 2-4.7 mg/day. Low dose of memantine having anti-inflammatory and neurotrophic effect is able to reduce alcohol use.

Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.

Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.

Abstract: Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine.

Abstract: A compound of formula I: wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2CH2—OH, C1-4alkylthio, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, C1

Abstract: Embodiments disclosed herein provide compositions, depot gel injections, and sustained-release drug delivery systems comprising urea and/or urea derivative and uses thereof.

Abstract: Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for promoting and/or accelerating myelination in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.

Abstract: Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.

Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

Abstract: The present invention provides methods for treating closed head injuries or hemorrhagic strokes using a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) may act as iron chelators to prevent formation of highly reactive radicals leading to additional damage in the closed head injuries or hemorrhagic strokes.

Abstract: Provided herein are compositions comprising amino acids and uses of such compositions to aid in recovery from exercise, illness or injury, in performance during exercise, in survival in extreme climatic conditions, and to reduce fatigue. The present disclosure relates to amino acid supplements, which may serve to supplement amino acids lost in sweat.

Abstract: The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione.

Abstract: The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.

Abstract: The present disclosure relates to pharmaceutical compositions for mammalian consumption containing essential fatty acids, protein, vitamins and choline, or combinations thereof, so constituted to optimize absorption and/or transport and/or efficiency of the co-ingredients of the composition. The pharmaceutical compositions are useful as supplements to provide nutrients to nutritionally deficient patients. The composition can contain essential fatty acids, such as EPA, DHA and/or ALA, cobalamin binding protein, such as Intrinsic Factor, vitamin B12 or a synthetic form thereof, choline, such as choline bitartrate, or combinations thereof.

Abstract: Provided are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of an agent which downregulates a mitochondrial aspartate-dependent pyrimidine synthesis, thereby treating the cancer.

Abstract: The concentrated liquid diet disclosed is a concentrated liquid diet having a total amount of a medium-chain fatty acid having 8 carbon atoms and a medium-chain fatty acid having 10 carbon atoms included as constitutive fatty acids of a triglyceride being 2.5 to 8.0 g per 100 kcal of the energy of the concentrated liquid diet, the concentrated liquid diet having in the total mass of the medium-chain fatty acid having 8 carbon atoms and the medium-chain fatty acid having 10 carbon atoms the rate of the medium-chain fatty acid having 10 carbon atoms being no less than 60% by mass, and the rate of the medium-chain fatty acid having 8 carbon atoms being no greater than 40% by mass.

Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.

Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.

Abstract: Disclosed herein are methods of using nutritional supplements and specific combinations thereof to counteract exercise-induced stress and its sequelae in members of the Equus species. Particular embodiments focus on use of Coenzyme Q10, vitamin E and their variants. Methods include ascertaining and modifying the nutritional supplements, ascertaining and comparing health states of a horse, wherein the comparisons are made before and after modifications of the supplements and/or implementation of exercise regimens.

Abstract: The present disclosure relates, according to some embodiments, to acetogenin molecules that may have antiplatelet and/or antithronibic activities. In some embodiments, the present disclosure relates to an acetogenin molecule selected from the group comprising: Acetogenin 1, Acetogenin 2, Acetogenin 3, Acetogenin 4, Acetogenin 5, Acetogenin 6, Acetogenin 7, Acetogenin 8, Acetogenin 9, Acetogenin 10, Acetogenin 11, Acetogenin 12, Acetogenin 13, and Acetogenin 14. The present disclosure relates in some embodiments to a pharmaceutical composition comprising a first acetogenin molecule and a delivery vehicle, wherein the first acetogenin molecule is selected from the group comprising: Acetogenin 1, Acetogenin 2, Acetogenin 3, Acetogenin 4, Acetogenin 5, Acetogenin 6, Acetogenin 7, Acetogenin 8, Acetogenin 9, Acetogenin 10, Acetogenin 11, Acetogenin 12, Acetogenin 13, and Acetogenin 14.

Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.